Trisha Michel Wise-Draper MD PhD
Head & Neck Cancer
Associate Professor of Medicine, Director of Medical Oncology Services, Medical Director UCCC Clinical Trials Office
Join to View Full Profile
234 Goodman StMl 0781Cincinnati, OH 45219
Phone+1 513-584-4505
Dr. Wise-Draper is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2013- University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2011
University of Cincinnati College of MedicineClass of 2010
Certifications & Licensure
OH State Medical License 2010 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
- Study of Letrozole in Recurrent Gliomas Start of enrollment: 2017 May 16
- Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy Start of enrollment: 2017 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infe...Emily Pei-Ying Lin, Chih-Yuan Hsu, Sanjay Mishra, Elizabeth A Griffiths, Brahm H Segal
Lancet Regional Health. Americas. 2025-04-01 - Early-phase clinical trials in the pandemic era: a four-year experience from an academic cancer center.Katie Moreland, Bethany Fuhrman, Kayla Webb, Melanie Margraf, Jessica Wernke
American Journal of Cancer Research. 2025-01-01 - Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry
Cancer Cell. 2024-12-09
Press Mentions
University of Cincinnati Cancer Experts Present Research at ASCO Annual MeetingMay 25th, 2023- Researchers Find Ways Immunotherapy Affects COVID-19 OutcomesNovember 6th, 2022
- A Potential New Treatment for Brain TumorsSeptember 23rd, 2022
- Join now to see all
Grant Support
- Optimization of peripheral blood mononuclear cell (PBMC) processing for robust downstream functional immune cell analysis and correlation with therapeutic efficacyUNIVERSITY OF CINCINNATI2022–2027
- Optimization of peripheral blood mononuclear cell (PBMC) processing for robust downstream functional immune cell analysis and correlation with therapeutic efficacyUNIVERSITY OF CINCINNATI2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
